alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information from consolidated financial
statements for the period ending March 31, 2000 and is qualified in its entirety
by reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                            5688
<SECURITIES>                                         0
<RECEIVABLES>                                    21743
<ALLOWANCES>                                       691
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 32511
<PP&E>                                          617864
<DEPRECIATION>                                   83884
<TOTAL-ASSETS>                                  699240
<CURRENT-LIABILITIES>                            27850
<BONDS>                                         400424
<COMMON>                                           285
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                      245781
<TOTAL-LIABILITY-AND-EQUITY>                    699240
<SALES>                                          26381
<TOTAL-REVENUES>                                 26381
<CGS>                                            30794
<TOTAL-COSTS>                                    30794
<OTHER-EXPENSES>                                   349
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                8344
<INCOME-PRETAX>                                (12926)
<INCOME-TAX>                                    (3865)
<INCOME-CONTINUING>                             (9061)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    (9061)
<EPS-BASIC>                                    (.32)
<EPS-DILUTED>                                    (.32)


</TABLE>
---

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial
Officer Pursuant to 18 U.S.C Section 1350

In connection with the annual report on Form 10-K of Helius
Medical Technologies, Inc. (the "Company") for the fiscal year ended March 31,
2016 as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), Philippe Deschamps, as Chief Executive Officer of the Company,
and Joyce LaViscount, as Chief Financial Officer of the Company, each hereby
certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

| | 1. | The Report fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
  and                                   
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------
| |    |                                                                                                                                                                 
| | 2. | The information contained in the Report fairly presents,
      in all material respects, the financial condition and results of
      operations of the Company.

Date: October 31, 2016

|/s/ Philippe
      Deschamps | 
|---------------------------- | 
|                             | 
|Philippe Deschamps           | 
|President, Chief Executive   | 
|Officer, and a Director      | 
|                             | 
|/s/ Joyce
      LaViscount   | 
|                             | 
|Joyce LaViscount             | 
|Chief Financial Officer      | 

A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this
written statement required by Section 906, has been provided to Helius Medical
Technologies, Inc. and will be retained by Helius Medical Technologies, Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.

---
584 A.2d 231

#### GERALD BRUNO AND ALFRED BECHARD v. CITY OF ATLANTIC CITY, ET AL.

May 30, 1990.

Petition for certification denied. (See 239 *N.J.Super.*469, 571 A.2d 1003)
[Federal Register Volume 75, Number 196 (Tuesday, October 12, 2010)]
[Notices]
[Pages 62568-62569]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-25282]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Federal Bureau of Investigation


Meeting of the Compact Council for the National Crime Prevention 
and Privacy Compact

AGENCY: Federal Bureau of Investigation.

ACTION: Meeting notice.

-----------------------------------------------------------------------

SUMMARY: The purpose of this notice is to announce a meeting of the 
National Crime Prevention and Privacy Compact Council (Council) created 
by the National Crime Prevention and Privacy Compact Act of 1998 
(Compact). Thus far, the Federal Government and 29 states are parties 
to the Compact which governs the exchange of criminal history records 
for licensing, employment, and similar purposes. The Compact also 
provides a legal framework for the establishment of a cooperative 
federal-state system to exchange such records. The United States 
Attorney General appointed 15 persons from state and federal agencies 
to serve on the Council. The Council will prescribe system rules and 
procedures for the effective and proper operation of the Interstate 
Identification Index system for noncriminal justice purposes.
    Matters for discussion are expected to include:
    (1) Benchmarks for the National Fingerprint File Program 
Participation

[[Page 62569]]

    (2) changes to the Security and Management control Outsourcing 
Standard for Channelers and Non-Channelers
    (3) Prioritization of the Compact Council Strategies
    The meeting will be open to the public on a first-come, first-
seated basis. Any member of the public wishing to file a written 
statement with the Council or wishing to address this session of the 
Council should notify the Federal Bureau of Investigation (FBI) Compact 
Officer, Mr. Gary S. Barron at (304) 625-2803, at least 24 hours prior 
to the start of the session. The notification should contain the 
requestor's name and corporate designation, consumer affiliation, or 
government designation, along with a short statement describing the 
topic to be addressed and the time needed for the presentation. 
Requesters will ordinarily be allowed up to 15 minutes to present a 
topic.
    Dates and Times: The Council will meet in open session from 9 a.m. 
until 5 p.m., on November 3-4, 2010.

ADDRESSES: The meeting will take place at the Renaissance Glendale 
Hotel, 9445 West Coyotes Boulevard, Glendale, Arizona, telephone (623) 
937-3700.

FOR FURTHER INFORMATION CONTACT: Inquiries may be addressed to Mr. Gary 
S. Barron, FBI Compact Officer, Compact Council Office, Module D3, 1000 
Custer Hollow Road, Clarksburg, West Virginia 26306, telephone (304) 
625-2803, facsimile (304) 625-2868.

    Dated: August 11, 2010.
Kimberly J. Del Greco,
Section Chief, Biometric Services Section Criminal Justice Information 
Services Division, Federal Bureau of Investigation.
[FR Doc. 2010-25282 Filed 10-8-10; 8:45 am]
BILLING CODE 4410-02-M
Exhibit 4.1


 


 


Advisors Asset Management, Inc.

18925 Base Camp Road

Monument, Colorado 80132


December 10, 2021


 


Advisors Disciplined Trust 2100


c/o The Bank of New York Mellon, as Trustee


240 Greenwich Street, 22W Floor


New York, NY 10286


 


Re: Advisors Disciplined Trust 2100 (the “Fund”)


Ladies and Gentlemen:


We have examined the Registration
Statement File No. 333-259541 for the above captioned Fund. We hereby consent to the use in the Registration Statement of the references
to Advisors Asset Management, Inc. as evaluator.


You are hereby authorized
to file a copy of this letter with the Securities and Exchange Commission.


 


	 	Very
    truly yours,
	 	 	 
	 	Advisors
    Asset Management, Inc.
	 	 	 
	 	 	 
	 	By	/s/
    ALEX R. MEITZNER
	 	 	Alex
    R. Meitzner
	 	 	Senior
    Vice President
EXHIBIT 13.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Cnova N.V. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Emmanuel Grenier, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

|   |                          |
|--------|-------------------------------|
|   | /s/ Emmanuel Grenier          |
|   | Emmanuel Grenier              |
|   | Chief Executive Officer       |
|   | (Principal Executive Officer) |
|   | Date: July 21, 2016           |

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

----
| (logo) WELLS FARGO | **Corporate Trust Services**

  MAC R1204-010  9062 Old Annapolis Road  Columbia, MD 21045  Tel: 410 884 2000  Fax: 410 715 2380 |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------|

 

 

J.P. Morgan Chase CommercialMortgage Securities Corp. 

383 Madison Avenue

31st Floor

New York, New York 10179

 

Re: Annual Statement ofCompliance for J.P. Morgan Chase Commercial Mortgage Securities Trust 2014-C20,Commercial Mortgage Pass-Through Certificates, Series 2014-C20

 

Per the Pooling and ServicingAgreement dated as of June 1, 2014 (the "Agreement"), theundersigned, a duly authorized officer of Wells Fargo Bank, N.A., asCertificate Administrator ("Wells Fargo"), hereby certifies asfollows as of and for the year ending December 31, 2016 (the "ReportingPeriod"):

 

(a) A review of Wells Fargo'sactivities during the Reporting Period and of its performance under theAgreement has been made under such officer's supervision; and

 

(b) To the best of suchofficer's knowledge, based on such review, Wells Fargo has fulfilled all of itsobligations under the Agreement in all material respects throughout theReporting Period.

 

 

February 27, 2017

 

 

/s/ Brian Smith

BRIAN SMITH

Vice President 

 

 

| Wells Fargo Bank, N.A. | (logo) Together we’ll  go far |
|------------------------|-------------------------------------|
**Exhibit 31.1**

 

**CERTIFICATION**

 

I, Robert B. Goergen,Chairman, Chief Executive Officer of Blyth, Inc., certify that:

 

1.                 I have reviewed thisquarterly report on Form 10-Q of Blyth, Inc.;

 

2.                 Based on my knowledge, thisreport does not contain any untrue statement of a material fact or omit tostate a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this report;

 

3.                 Based on my knowledge, thefinancial statements, and other financial information included in this report,fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periodspresented in this report;

 

4.                The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under our supervision,to ensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

 

(b)  Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

 

(c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during the registrant’smost recent fiscal quarter (the registrant’s fourth fiscal quarter in the caseof an annual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting; and

 

5.                 The registrant’s othercertifying officer(s) and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of the registrant’s board of directors (or personsperforming the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reporting which arereasonably likely to adversely affect the registrant’s ability to record,process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves managementor other employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 

 

Date: April 14, 2005

 
|                  |
|-----------------------|
| /s/ Robert B. Goergen |   |

Robert B. Goergen

Chairman, Chief ExecutiveOfficer

 

----
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                                            <C>
<PERIOD-TYPE>                                  3-MOS
<FISCAL-YEAR-END>                              NOV-30-1999
<PERIOD-END>                                   FEB-28-1999
<CASH>                                                  83
<SECURITIES>                                             0
<RECEIVABLES>                                        1,096
<ALLOWANCES>                                            12
<INVENTORY>                                          1,989
<CURRENT-ASSETS>                                     7,168
<PP&E>                                                   0
<DEPRECIATION>                                           0
<TOTAL-ASSETS>                                       7,310
<CURRENT-LIABILITIES>                                  204
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              1
<COMMON>                                                 0
<OTHER-SE>                                           7,105
<TOTAL-LIABILITY-AND-EQUITY>                         7,310
<SALES>                                              1,748
<TOTAL-REVENUES>                                     1,748
<CGS>                                                  991
<TOTAL-COSTS>                                          991
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                       (180)
<INCOME-TAX>                                           (94)
<INCOME-CONTINUING>                                    (86)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                           (86)
<EPS-PRIMARY>                                         (.06)
<EPS-DILUTED>                                         (.06)
        


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1
       
<S>                        <C>
<PERIOD-TYPE>              3-MOS
<FISCAL-YEAR-END>                         DEC-31-1997
<PERIOD-START>                            JUL-01-1997
<PERIOD-END>                              SEP-30-1997
<CASH>                                        638,504
<SECURITIES>                                        0
<RECEIVABLES>                                 262,903
<ALLOWANCES>                                   25,000
<INVENTORY>                                   128,870
<CURRENT-ASSETS>                            1,005,277
<PP&E>                                      2,853,342
<DEPRECIATION>                                165,610
<TOTAL-ASSETS>                              4,296,661
<CURRENT-LIABILITIES>                         906,289
<BONDS>                                             0
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<COMMON>                                       35,702
<OTHER-SE>                                  2,447,105
<TOTAL-LIABILITY-AND-EQUITY>                4,296,661
<SALES>                                       147,916      
<TOTAL-REVENUES>                              147,916      
<CGS>                                         517,466      
<TOTAL-COSTS>                               1,154,257        
<OTHER-EXPENSES>                                    0
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                             21,984
<INCOME-PRETAX>                              (992,023)
<INCOME-TAX>                                        0
<INCOME-CONTINUING>                          (992,023)
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                                 (992,023)
<EPS-PRIMARY>                                    (.28)
<EPS-DILUTED>                                    (.28)


</TABLE>
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 720 Introduced in House (IH)]

<DOC>

115th CONGRESS
  1st Session
                                H. R. 720

  To amend Rule 11 of the Federal Rules of Civil Procedure to improve 
            attorney accountability, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            January 30, 2017

Mr. Smith of Texas (for himself, Mr. Goodlatte, Mr. Buck, Mr. Franks of 
 Arizona, Mr. Farenthold, Mr. Chabot, and Mr. Chaffetz) introduced the 
  following bill; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
  To amend Rule 11 of the Federal Rules of Civil Procedure to improve 
            attorney accountability, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Lawsuit Abuse Reduction Act of 
2017''.

SEC. 2. ATTORNEY ACCOUNTABILITY.

    (a) Sanctions Under Rule 11.--Rule 11(c) of the Federal Rules of 
Civil Procedure is amended--
            (1) in paragraph (1), by striking ``may'' and inserting 
        ``shall'';
            (2) in paragraph (2), by striking ``Rule 5'' and all that 
        follows through ``motion.'' and inserting ``Rule 5.''; and
            (3) in paragraph (4), by striking ``situated'' and all that 
        follows through the end of the paragraph and inserting 
        ``situated, and to compensate the parties that were injured by 
        such conduct. Subject to the limitations in paragraph (5), the 
        sanction shall consist of an order to pay to the party or 
        parties the amount of the reasonable expenses incurred as a 
        direct result of the violation, including reasonable attorneys' 
        fees and costs. The court may also impose additional 
        appropriate sanctions, such as striking the pleadings, 
        dismissing the suit, or other directives of a non-monetary 
        nature, or, if warranted for effective deterrence, an order 
        directing payment of a penalty into the court.''.
    (b) Rule of Construction.--Nothing in this Act or an amendment made 
by this Act shall be construed to bar or impede the assertion or 
development of new claims, defenses, or remedies under Federal, State, 
or local laws, including civil rights laws, or under the Constitution 
of the United States.
                                 <all>
```
No. 13,510.

#### Lindeman et al. v. The Town of Monticello.

Filed Jan. 26, 1889;

petition for a rehearing overruled March 26, 1889.

From the White Circuit Court.

*A. W. Reynolds*and *E. B. Sellers,*for appellants.

Mitchell, J.

The judgment in this case is controlled by the decision, in *Vinson*v. *Town of Monticello, ante,*p. 103.

Judgment affirmed, with costs, and five per cent, damages.
AMENDMENT TO
             RESEARCH COLLABORATION AND LICENSE AGREEMENT (U.S.)

  This Amendment to the Research Collaboration and License Agreement (U.S.)
is entered into as of this 12th day of June, 1998 by and between Biogen,
Inc., a Massachusetts corporation located at 14 Cambridge Center, Cambridge,
MA  02142 ("Biogen") and CV Therapeutics, Inc., a Delaware corporation with
principal offices located at 3172 Porter Drive, Palo Alto, CA  94304 ("CVT").

  WHEREAS, Biogen and CVT are parties to a certain Research Collaboration
and License Agreement (U.S.), dated as of March 7, 1997 (the "U.S. Research
Agreement") and Biotech Manufacturing Ltd. ("BML") and CVT are parties to a
certain Loan Agreement dated as of March 7, 1997 (the "Loan Agreement") in
connection therewith; and 

  WHEREAS, in connection with the amendment to the Loan Agreement, the
parties desire to amend the U.S. Research Agreement to change the definition
of "Performance Assessment Study";

  NOW, THEREFORE, in consideration of the premises and mutual covenants
contained in this Amendment, the parties agree as follows:

  1.  Definitions.

      The capitalized terms used in this Amendment shall have the meanings
      assigned to such terms in the U.S. Research Agreement.

  2.  Amended provisions.

      Biogen and CVT agree that the U.S. Research Agreement shall be amended
      in the manner set forth below:

      (a)    Section 1.19 of the U.S. Research Agreement is amended to be,
             and read, in its entirety as follows:

      The term "PHASE II PERFORMANCE ASSESSMENT STUDY" shall mean the
      clinical study known as BG1205.

  3.  Ratification.

      Except as otherwise expressly set forth in this Amendment, all of the
      terms and conditions of the Loan Agreement shall remain in full force
      and effect.

  IN WITNESS WHEREOF, the parties have executed this Amendment on the date
first above written.


BIOGEN, INC.                    CV THERAPEUTICS, INC.



By:       /s/ James R. Tobin           By:       /s/ Louis G. Lange
                                
Title:   Chief Executive Officer       Title:   Chief Executive Officer